HDL-associated enzymes and proteins in hemodialysis patients

Clinical Biochemistry

Volumn 45, Issue 3, 2012, Pages 243-248

  Cacciagiú, Leonardo D ^a   González, Ana I ^a   Rosso, Leonardo Gomez ^a   Meroño, Tomás ^a   De Marziani, Guillermo ^b   Elbert, Alicia ^b   Berg, Gabriela ^a   Brites, Fernando ^a   Schreier, Laura ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Kidney Disease Center and Arterial Hypertension (CEREHA)   (Argentina)

Author keywords

Cholesteryl ester transfer protein; HDL; Hemodialysis; Hepatic lipase; Lipoprotein associated phospholipase A 2; Paraoxonase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIPOLYSIS; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; OXIDATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; ENZYMES; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RENAL DIALYSIS; STATISTICS, NONPARAMETRIC;

EID: 84856458493     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.12.008     Document Type: Article

References (48)

1. González A.I., Schreier L., Elbert A., Berg G., Beresan H., López G., et al. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients. Metabolism 2003, 52:116-121.
2. Vaziri N.D. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 2009, 22:644-651.
3. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:473-480.
4. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
5. Barter P.J., Puranik R., Rye K.A. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 2007, 9:493-498.
6. de Grooth G.J., Klerkx A.H., Stroes E.S., Stalenhoef A.F., Kastelein J.J., Kuivenhoven J.A. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004, 45:1967-1974.
7. Yazdanyar A., Yeang C., Jiang X.C. Role of phospholipid transfer protein in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep 2011, 13(3):242-248.
8. Annema W., Tietge U.J. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep 2011, 13(3):257-265.
9. Fan J., Wang J., Bensadoun A., Lauer S.J., Dang Q., Mahley R.W., et al. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci U S A 1994, 30(91):8724-8728.
10. MacPhee C.H., Moores K.E., Boyd H.F., Dhanak D., Ife R.J., Leach C.A., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999, 338:479-487.
11. Tjoelker L.W., Wilder C., Eberhardt C., Stafforini D.M., Dietsch G., Schimpf B., et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995, 374:549-553.
12. Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25:923-931.
13. Lagrost L., Gandjini H., Athias A., Guyard-Dangremont V., Lallemant C., Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb 1993, 13:815-825.
14. Brites F.D., Verona J., Schreier L.E., Fruchart J.C., Castro G.R., Wikinski R.L. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low HDL-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res 2004, 35:235-240.
15. La Du B.N., Eckerson H.W. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 1984, 43(8):2338-2341.
16. Blank M.L., Hall M.N., Cress E.A., Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun 1983, 113:666-671.
17. Muzzio M.L., Berg G., Zago V., Basilio F., Sanguinetti S., Lopez G., et al. Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women. Clin Chim Acta 2007, 381:157-163.
18. Mackness M.I., Durrington P.N., Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004, 4:211-217.
19. Moldoveanu E., Tanaseanu C., Tanaseanu S., Kosaka T., Manea G., Marta D.S., et al. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med 2006, 17:38-42.
20. Sanguinetti S.M., Brites F.D., Fasulo V., Verona J., Elbert A., Wikinski R.L., et al. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients. Diabetes Nutr Metab 2001, 14:27-36.
21. Suehiro T., Ikeda Y., Shiinoki T., Inoue M., Kumon Y., Itahara T., et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002, 9:133-138.
22. Dirican M., Akca R., Sarandol E., Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004, 17:813-818.
23. Mackness M.I., Walker C.H. 'A'-esterase activity in the lipoprotein fraction of sheep serum. Biochem Pharmacol 1981, 30:903-906.
24. Blatter M.C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993, 211:871-879.
25. Juretić D., Tadijanović M., Rekić B., Simeon-Rudolf V., Reiner E., Baricić M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 2001, 42:146-150.
26. Packard C.J., O'Reilly D.S., Caslake M.J., McMahon A.D., Ford I., Cooney J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343:1148-1155.
27. Oei H.H., Sayed-Tabatabaei F.A., Hofman A., Oudkerk M., van Duijn C.M., Witteman J.C. The association between angiotensin-converting enzyme gene polymorphism and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis 2005, 182:169-173.
28. Meade C.J., Birke F., Metcalfe S., Watson C., Jamieson N., Neild G. Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation. J Lipid Mediat Cell Signal 1994, 9:205-215.
29. Hasselwander O., McMaster D., Fogarty D.G., Maxwell A.P., Nicholls D.P., Young I.S. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998, 44:179-181.
30. Milionis H.J., Elisaf M.S., Karabina S.A., Bairaktari E., Tselepis A.D., Siamopoulos K.C. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures. Kidney Int 1999, 56:2276-2285.
31. Liu J., Rosner M.H. Lipid abnormalities associated with end-stage renal disease. Semin Dial 2006, 19:32-40.
32. Papavasiliou E.C., Gouva C., Siamopoulos K.C., Tselepis A.D. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant 2006, 21:1270-1277.
33. Garcia-Garcia H.M., Serruys P.W. Phospholipase A2 inhibitors. Curr Opin Lipidol 2009, 20:327-332.
34. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Emerging Risk Factors Collaboration. Lancet 2010, 375:132-140.
35. Kaysen G.A., Eiserich J.P. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial 2003, 16:438-446.
36. Kato A., Takita T., Furuhashi M., Maruyama Y., Hishida A. Comparison of serum albumin, C-reactive protein and carotid atherosclerosis as predictors of 10-year mortality in hemodialysis patients. Hemodial Int 2010, 14:226-232.
37. Yin K., Liao D.F., Tang C.K. ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol Med 2010, 16:438-449.
38. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96:2758-2767.
39. Haas M.J., Horani M., Mreyoud A., Plummer B., Wong N.C., Mooradian A.D. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. Biochim Biophys Acta 2003, 1623:120-128.
40. Kaysen G.A. Disorders in high-density metabolism with insulin resistance and chronic kidney disease. J Ren Nutr 2007, 17:4-8.
41. Ansell B.J., Fonarow G.C., Fogelman A.M. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007, 18:427-434.
42. González A.I., Brites F., Elbert A., Gómez-Rosso L., Berg G., Wikinski R., et al. Relation between paraoxonase activity, other HDL components and inflammatory state in hemodialyzed patients. Medicina 2010, 70:508-512.
43. Jurek A., Turyna B., Kubit P., Klein A. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem 2006, 39:19-27.
44. Moradi H., Pahl M.V., Elahimehr R., Vaziri N.D. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009, 153:77-85.
45. de Grooth G.J., Smilde T.J., Van Wissen S., Klerkx A.H., Zwinderman A.H., Fruchart J.C., et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004, 173:261-267.
46. Zago V., Sanguinetti S., Brites F., Berg G., Verona J., Basilio F., et al. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 2004, 177:203-210.
47. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997, 17(12):3542-3556.
48. Attia N., Domingo N., Lorec A.M., Nakbi A., Hammami S., Ben Hamda K., et al. Reverse modulation of the HDL anionic peptide factor and phospholipid transfer protein activity in coronary artery disease and type 2 diabetes mellitus. Clin Biochem 2009, 42(9):845-851.